Full Press Release Details
| Surveillance Department BSE Limited Dalal Street, Fort Mumbai 400 001 | National Stock Exchange of India Ltd. Exchange Plaza Bandra-Kurla Complex, Bandra (East), Mumbai 400 051 | |||||||||
| Fax Nos.: | 22-22723121 / 22723719 / 22722037 / 22722039 | Fax Nos.: | 022-26598120/ 26598237/ 26598238 | |||||||
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
email dated September 1, 2017
Sub: Clarification on news item appearing in Business Line dated September 1, 2017 captioned Dr.
Reddy s settles patent row with Vivus.
This is with reference to your email dated September 1, 2017, seeking clarification on the above
The Company confirms the reaching of a settlement with Vivus, as stated in their press release. The Company believes that litigation and
settlement related to patent is usual and is in the normal course of pharmaceutical business operations. Further, the overall impact on the Company s financials of settlement of patent disputes with Vivus is not likely to be material.
We regularly inform all concerned about material events. Today, the Company informed the stock exchanges regarding the favorable judgment issued last night by
the United States District Court, for the District of Delaware, on the proposed generic version of Suboxone sublingual film, which may seem to be material, under relevant circumstances.
This is for your information.
| With regards, |
| /s/ Sandeep Poddar |
| Sandeep Poddar Company Secretary |
CC:- New York Stock Exchange Inc. (Stock Code: RDY)